SCHEMBL368404

SCHEMBL368404

COc1ccc(-n2c(=NC#N)n(C)c3cnc4ccc(-c5cccnc5)cc4c32)c(OC)c1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PIK3CD O00329 7/20 0.50
PIK3CB P42338 4/20 0.46
PIK3CG P48736 4/20 0.46
PIK3CA P42336 3/20 0.46
MTOR P42345 3/20 0.46
MAPK1 P28482 4/20 0.44
LMNA P02545 3/20 0.44
CYP1A2 P05177 3/20 0.44
CYP3A4 P08684 3/20 0.44
CYP2D6 P10635 3/20 0.44
USP2 O75604 2/20 0.44
CYP2C19 P33261 2/20 0.44
HSD17B10 Q99714 2/20 0.44
CLK4 Q9HAZ1 2/20 0.44
ATM Q13315 2/20 0.44
ATR Q13535 2/20 0.44
KCNH2 Q12809 1/20 0.44
CYP11B2 P19099 5/20 0.41
CYP11B1 P15538 3/20 0.41
CYP17A1 P05093 2/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL368403 1.00 PIK3CD (0.50) PIK3CDPIK3CBPIK3CGPIK3CAMTOR
SCHEMBL368332 0.90 PIK3CD (0.44) PIK3CDPIK3CBPIK3CGPIK3CAMTOR
SCHEMBL368331 0.90 PIK3CD (0.44) PIK3CDPIK3CBPIK3CGPIK3CAMTOR
SCHEMBL368938 0.88 PIK3CD (0.51) PIK3CDPIK3CBPIK3CGPIK3CAMTOR
SCHEMBL368937 0.88 PIK3CD (0.51) PIK3CDPIK3CBPIK3CGPIK3CAMTOR
SCHEMBL369854 0.87 MTOR (0.51) PIK3CDPIK3CBPIK3CGPIK3CAMTOR
SCHEMBL369855 0.87 MTOR (0.51) PIK3CDPIK3CBPIK3CGPIK3CAMTOR
SCHEMBL369024 0.86 PIK3CD (0.41) PIK3CDPIK3CBPIK3CGPIK3CAMTOR
SCHEMBL369025 0.86 PIK3CD (0.41) PIK3CDPIK3CBPIK3CGPIK3CAMTOR
SCHEMBL368433 0.85 PIK3CD (0.46) PIK3CDPIK3CBPIK3CGPIK3CAMTOR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2593450-A1 SUBSTITUTED IMIDAZOQUINOLINE DERIVATIVES AS KINASE INHIBITORS Piramal Enterprises Limited (IN) 2013-05-22 EP claimed
US-20130116248-A1 SUBSTITUTED IMIDAZOQUINOLINE DERIVATIVES AS KINASE INHIBITORS Piramal Enterprises Limited (IN) 2013-05-09 US claimed
WO-2012007926-A1 SUBSTITUTED IMIDAZOQUINOLINE DERIVATIVES AS KINASE INHIBITORS PIRAMAL LIFE SCIENCES LIMITED (IN) 2012-01-19 WO claimed
US-9062046-B2 Substituted imidazoquinoline derivatives as kinase inhibitors Piramal Enterprises Limited (IN) 2015-06-23 US disclosed
EP-2593450-A1 SUBSTITUTED IMIDAZOQUINOLINE DERIVATIVES AS KINASE INHIBITORS Piramal Enterprises Limited (IN) 2013-05-22 EP disclosed
US-20130116248-A1 SUBSTITUTED IMIDAZOQUINOLINE DERIVATIVES AS KINASE INHIBITORS Piramal Enterprises Limited (IN) 2013-05-09 US disclosed
WO-2012007926-A1 SUBSTITUTED IMIDAZOQUINOLINE DERIVATIVES AS KINASE INHIBITORS PIRAMAL LIFE SCIENCES LIMITED (IN) 2012-01-19 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130116248-A1 SUBSTITUTED IMIDAZOQUINOLINE DERIVATIVES AS KINASE INHIBITORS CDK2, CDK4, MAP3K1 PIK3CD 115/4885PIK3CB 109/4885PIK3CG 139/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.